Esthesioneuroblastoma: Prognosis and management

Akio Morita, Michael J. Ebersold, Kerry D. Olsen, Robert L. Foote, Jean E. Lewis, Lynn M. Quast

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

FORTY-NINE PATIENTS WITH esthesioneuroblastoma were treated at the Mayo Clinic between 1951 and 1990. Their clinical manifestations and treatment results were reviewed to identify possible prognostic factors. The 5-year survival rate for all patients was 69%. Tumor progression occurred in 25 patients (51%; no local control in 6 and local recurrence in 19). Metastasis was found in 15 patients (31%; regional in 10 and distant in 9). Nineteen patients died directly from metastatic or intracranial tumor extension. The pathological grade of the tumor was the most significant prognostic factor identified. The 5-year survival rate was 80% for the low-grade tumors and 40% for the high-grade tumors (P = 0.0001). Surgical treatment alone is effective for low-grade tumors if tumor-free margins can be obtained. Radiation is used for low-grade tumors when margins are close, for residual or recurrent disease, and for all high-grade cancers. The poor prognosis associated with high-grade tumors may also mandate the addition of chemotherapy. Recurrent tumor and regional metastasis should be treated aggressively because this approach has been shown to be worthwhile. A craniofacial resection is now the surgical procedure performed in all cases. Because recurrence can occur after 5 or even 10 years, long-term follow-up is mandatory.

Original languageEnglish (US)
Pages (from-to)706-715
Number of pages10
JournalNeurosurgery
Volume32
Issue number5
StatePublished - 1993

Fingerprint

Olfactory Esthesioneuroblastoma
Neoplasms
Survival Rate
Neoplasm Metastasis
Recurrence

Keywords

  • Craniofacial approach
  • Esthesioneuroblastoma
  • Pathological differentiation
  • Radiation treatment
  • Salvage treatment

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Clinical Neurology

Cite this

Morita, A., Ebersold, M. J., Olsen, K. D., Foote, R. L., Lewis, J. E., & Quast, L. M. (1993). Esthesioneuroblastoma: Prognosis and management. Neurosurgery, 32(5), 706-715.

Esthesioneuroblastoma : Prognosis and management. / Morita, Akio; Ebersold, Michael J.; Olsen, Kerry D.; Foote, Robert L.; Lewis, Jean E.; Quast, Lynn M.

In: Neurosurgery, Vol. 32, No. 5, 1993, p. 706-715.

Research output: Contribution to journalArticle

Morita, A, Ebersold, MJ, Olsen, KD, Foote, RL, Lewis, JE & Quast, LM 1993, 'Esthesioneuroblastoma: Prognosis and management', Neurosurgery, vol. 32, no. 5, pp. 706-715.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: Prognosis and management. Neurosurgery. 1993;32(5):706-715.
Morita, Akio ; Ebersold, Michael J. ; Olsen, Kerry D. ; Foote, Robert L. ; Lewis, Jean E. ; Quast, Lynn M. / Esthesioneuroblastoma : Prognosis and management. In: Neurosurgery. 1993 ; Vol. 32, No. 5. pp. 706-715.
@article{a0ec855d364342baa476ba2f20669a05,
title = "Esthesioneuroblastoma: Prognosis and management",
abstract = "FORTY-NINE PATIENTS WITH esthesioneuroblastoma were treated at the Mayo Clinic between 1951 and 1990. Their clinical manifestations and treatment results were reviewed to identify possible prognostic factors. The 5-year survival rate for all patients was 69{\%}. Tumor progression occurred in 25 patients (51{\%}; no local control in 6 and local recurrence in 19). Metastasis was found in 15 patients (31{\%}; regional in 10 and distant in 9). Nineteen patients died directly from metastatic or intracranial tumor extension. The pathological grade of the tumor was the most significant prognostic factor identified. The 5-year survival rate was 80{\%} for the low-grade tumors and 40{\%} for the high-grade tumors (P = 0.0001). Surgical treatment alone is effective for low-grade tumors if tumor-free margins can be obtained. Radiation is used for low-grade tumors when margins are close, for residual or recurrent disease, and for all high-grade cancers. The poor prognosis associated with high-grade tumors may also mandate the addition of chemotherapy. Recurrent tumor and regional metastasis should be treated aggressively because this approach has been shown to be worthwhile. A craniofacial resection is now the surgical procedure performed in all cases. Because recurrence can occur after 5 or even 10 years, long-term follow-up is mandatory.",
keywords = "Craniofacial approach, Esthesioneuroblastoma, Pathological differentiation, Radiation treatment, Salvage treatment",
author = "Akio Morita and Ebersold, {Michael J.} and Olsen, {Kerry D.} and Foote, {Robert L.} and Lewis, {Jean E.} and Quast, {Lynn M.}",
year = "1993",
language = "English (US)",
volume = "32",
pages = "706--715",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Esthesioneuroblastoma

T2 - Prognosis and management

AU - Morita, Akio

AU - Ebersold, Michael J.

AU - Olsen, Kerry D.

AU - Foote, Robert L.

AU - Lewis, Jean E.

AU - Quast, Lynn M.

PY - 1993

Y1 - 1993

N2 - FORTY-NINE PATIENTS WITH esthesioneuroblastoma were treated at the Mayo Clinic between 1951 and 1990. Their clinical manifestations and treatment results were reviewed to identify possible prognostic factors. The 5-year survival rate for all patients was 69%. Tumor progression occurred in 25 patients (51%; no local control in 6 and local recurrence in 19). Metastasis was found in 15 patients (31%; regional in 10 and distant in 9). Nineteen patients died directly from metastatic or intracranial tumor extension. The pathological grade of the tumor was the most significant prognostic factor identified. The 5-year survival rate was 80% for the low-grade tumors and 40% for the high-grade tumors (P = 0.0001). Surgical treatment alone is effective for low-grade tumors if tumor-free margins can be obtained. Radiation is used for low-grade tumors when margins are close, for residual or recurrent disease, and for all high-grade cancers. The poor prognosis associated with high-grade tumors may also mandate the addition of chemotherapy. Recurrent tumor and regional metastasis should be treated aggressively because this approach has been shown to be worthwhile. A craniofacial resection is now the surgical procedure performed in all cases. Because recurrence can occur after 5 or even 10 years, long-term follow-up is mandatory.

AB - FORTY-NINE PATIENTS WITH esthesioneuroblastoma were treated at the Mayo Clinic between 1951 and 1990. Their clinical manifestations and treatment results were reviewed to identify possible prognostic factors. The 5-year survival rate for all patients was 69%. Tumor progression occurred in 25 patients (51%; no local control in 6 and local recurrence in 19). Metastasis was found in 15 patients (31%; regional in 10 and distant in 9). Nineteen patients died directly from metastatic or intracranial tumor extension. The pathological grade of the tumor was the most significant prognostic factor identified. The 5-year survival rate was 80% for the low-grade tumors and 40% for the high-grade tumors (P = 0.0001). Surgical treatment alone is effective for low-grade tumors if tumor-free margins can be obtained. Radiation is used for low-grade tumors when margins are close, for residual or recurrent disease, and for all high-grade cancers. The poor prognosis associated with high-grade tumors may also mandate the addition of chemotherapy. Recurrent tumor and regional metastasis should be treated aggressively because this approach has been shown to be worthwhile. A craniofacial resection is now the surgical procedure performed in all cases. Because recurrence can occur after 5 or even 10 years, long-term follow-up is mandatory.

KW - Craniofacial approach

KW - Esthesioneuroblastoma

KW - Pathological differentiation

KW - Radiation treatment

KW - Salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=0027221616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027221616&partnerID=8YFLogxK

M3 - Article

C2 - 8492845

AN - SCOPUS:0027221616

VL - 32

SP - 706

EP - 715

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -